Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06594939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06594939 · ClinicalTrials.gov record · last posted 2026-08-25

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started2026-06-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.

Protocol amendment history 1 change detected by DataLookout

2026-08-26
Recruitment opened
Trial Details
NCT Number NCT06594939
Lead Sponsor Medical College of Wisconsin
Conditions Diffuse Large B Cell Lymphoma (DLBCL)
Enrollment 31 participants
Start Date 2026-06-01
Primary Completion 2028-06 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-25